Dataset Information


Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment.

ABSTRACT: There is no consensus on the optimal treatment for patients with advanced non-small-cell lung cancer (NSCLC) and stable disease (SD) after gefitinib therapy. This randomized, open-label, multicenter study aimed to explore whether dose-escalation of gefitinib would improve response and survival in NSCLC patients who achieved SD after one-month of standard gefitinib dosage. Between May 2009 and January 2012, 466 patients were enrolled and 100 eligible patients were randomized (1:1) to receive either a higher dose (500 mg/d; H group) or to continue standard dose (250 mg/d; S group) of gefitinib. Objective response rate (ORR) was similar between the two groups (12.5% vs 12.5%, p = 1.000). There were no significant differences regarding progression-free survival (PFS) and overall survival (OS) between both arms (H group vs S group: median PFS, 5.30 months vs 6.23 months, p = 0.167; median OS, 13.70 months vs 18.87 months, p = 0.156). Therefore, dose-escalation of gefitinib does not confer a response or survival advantage in patients who achieve SD with one month of standard-dose gefitinib treatment.

PROVIDER: S-EPMC4516974 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC5093174 | BioStudies
| S-EPMC5362536 | BioStudies
| S-EPMC6473268 | BioStudies
| S-EPMC4246704 | BioStudies
| S-EPMC7852511 | BioStudies
| S-EPMC6527523 | BioStudies
| S-EPMC4720098 | BioStudies
| S-EPMC4521154 | BioStudies
2017-01-01 | S-EPMC5559626 | BioStudies
| S-EPMC6484288 | BioStudies